Digital An open call for innovation There is a bright future ahead for open innovation in pharma, as Almirall executive vice-president, research and development chief scientific officer Karl Ziegelbauer explains.
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.